Foghorn Therapeutics, Inc. (FHTX)

NASDAQ: FHTX · IEX Real-Time Price · USD
6.23
-0.43 (-6.46%)
Dec 9, 2022 4:00 PM EST - Market closed
-6.46%
Market Cap 278.40M
Revenue (ttm) 15.76M
Net Income (ttm) -109.14M
Shares Out 41.67M
EPS (ttm) -2.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 63,494
Open 6.59
Previous Close 6.66
Day's Range 6.22 - 6.71
52-Week Range 6.22 - 24.34
Beta 1.94
Analysts Buy
Price Target 21.68 (+248.0%)
Earnings Date Nov 8, 2022

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; ... [Read more]

Industry Biotechnology
IPO Date Oct 23, 2020
Employees 119
Stock Exchange NASDAQ
Ticker Symbol FHTX
Full Company Profile

Financial Performance

In 2021, FHTX's revenue was $1.32 million, an increase of 206.74% compared to the previous year's $430,000. Losses were -$101.32 million, 47.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is 21.68, which is an increase of 247.99% from the latest price.

Price Target
$21.68
(247.99% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hem...

CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by c...

4 days ago - GlobeNewsWire

Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by c...

2 weeks ago - GlobeNewsWire

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Ant...

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by c...

1 month ago - GlobeNewsWire

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...

1 month ago - Zacks Investment Research

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

- FHD-286 Phase 1 dose escalation study in metastatic uveal melanoma continues to progress with initial data expected in the first half of 2023

1 month ago - GlobeNewsWire

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by c...

1 month ago - GlobeNewsWire

Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 161.2% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

1 month ago - Zacks Investment Research

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Se...

Initial Phase 1 data of FHD-609 show degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies

1 month ago - GlobeNewsWire

Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by c...

1 month ago - GlobeNewsWire

Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...

2 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such in...

2 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

New York, New York--(Newsfile Corp. - September 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such inv...

3 months ago - Newsfile Corp

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...

3 months ago - GlobeNewsWire

Foghorn Therapeutics Announces Change to Board of Directors

Foghorn Congratulates Co-Founder Cigall Kadoch on HHMI Appointment and Change in Role to Scientific Advisor to the Board Foghorn Congratulates Co-Founder Cigall Kadoch on HHMI Appointment and Change in ...

3 months ago - GlobeNewsWire

Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

3 months ago - Zacks Investment Research

Foghorn's stock falls 18% after disclosing clinical hold

Shares of Foghorn Therapeutics Inc. FHTX, -6.79% tumbled 18.4% in premarket trading on Tuesday after the company said the Food and Drug Administration put a full clinical hold on a Phase 1 clinical tria...

3 months ago - Market Watch

Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression th...

3 months ago - GlobeNewsWire

Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression th...

3 months ago - GlobeNewsWire

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -24.53% and 68.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

- FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS

4 months ago - GlobeNewsWire

Foghorn Therapeutics Announces Upcoming Investor Conference Participation

CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determi...

6 months ago - GlobeNewsWire

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ: FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodyspl...

6 months ago - Benzinga

Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression thr...

6 months ago - GlobeNewsWire

Foghorn Therapeutics Provides First Quarter 2022 Corporate Update

- Foghorn continues to advance three phase 1 studies through selectively targeting the chromatin regulatory system; both FHD-286 and FHD-609 continue to dose escalate and enroll patients with initial cl...

7 months ago - GlobeNewsWire

Foghorn Therapeutics Presents New Preclinical Data on Novel BRG1/BRM Inhibitor FHD-286 at the 2022 AACR Annual Meeting

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically deter...

7 months ago - GlobeNewsWire